Tara H. Lines

Tara H. Lines

Auto-generated profile, based on publicly available information

Tara H. Lines

Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
TLTara H. Lines
Tara H. Lines
WNWhitney J. Nesbitt
Whitney J. Nesbitt
MGMatthew H. Greene
Matthew H. Greene
GNGeorge E. Nelson
George E. Nelson
Objective: To evaluate the impact of a pharmacist-driven Staphylococcus aureus bacteremia (SAB) safety bundle supported by leadership and to compare compliance before and after implementation.Design: Retrospective cohort study with descriptive and before-and-after analyses.Setting: Tertiary-care academic medical center.Patients: All patients with documented SAB, regardless of the source of infection, were included. Patients transitioned to palliative care were excluded from before-and-after analysis.Methods: A pharmacist-driven safety bundle including documented clearance of bacteremia, echocardiography, removal of central venous catheters, and targeted intravenous therapy of at least 2 weeks duration was implemented in November 2015 and was supported by leadership with stepwise escalation for nonresponse. A descriptive analysis of all patients with SAB during the study period included pharmacy interventions, acceptance rates, and escalation rates. A pre–post implementation analysis of 100 sequential patients compared bundle compliance and descriptive parameters.Results: Overall, 391 interventions were made in the 20-month period following implementation, including 20 “good saves” avoiding potentially major adverse events. No statistically significant differences in complete bundle compliance were detected between the periods (74% vs 84%; P = .08). However, we detected a significant increase in echocardiography after the bundle was implemented (83% vs 94%; P = .02) and fewer patients received suboptimal definitive therapy after the bundle was implemented (10% vs 3%; P = .045).Conclusions: This pharmacist-driven SAB safety bundle with leadership support showed improvement in process measures, which may have prevented major adverse events, even with available infectious diseases (ID) consultation. It provides a critical safety net for institutions without mandatory ID consultation or with limited antimicrobial stewardship resources.

7 June 2018 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
TLTara H. Lines
Tara H. Lines
WNWhitney J. Nesbitt
Whitney J. Nesbitt
GNGeorge E. Nelson
George E. Nelson
Understanding provider perceptions of antimicrobial use (AU) feedback is important for optimal implementation. A survey addressing AU attribution scenarios, feedback methods, and implementation barriers was distributed to inpatient providers. As AU scenarios became more complex, disagreement regarding AU attribution arose. All providers were highly concerned about barriers to AU reporting.